Phase 1 N=68 Pharmacokinetic Evaluation of Intranasal Nalmefene
Pharmacokinetics
Primary: Maximum Plasma Concentration (Cmax) — 12.2; 1.77 ng/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=48 Assessment of Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome
Bone Marrow Edema
Primary: Reduction of the Edema Area — 64.53; 23.97 percentage of edema volume — p==0.006
Phase 2 N=40 Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer
Locally Advanced Breast Cancer · Metastatic Breast Cancer
Primary: Percentage of Patients Without Disease Progression — 7; 8 Participants
N/A N=34 Longitudinal Outcomes of Hearing Aids
Presbycusis
Primary: Hearing Aid Benefit as Measured by the Glasgow Hearing Aid Benefit Profile (GHABP) — 3.68; 3.55; 3.63 score on a scale
N/A N=16 Implementation of a Telehealth Palliative Care Model for Persons With Dementia
Palliative Care · Dementia
Primary: Adherence to Skilled Nursing Facility (SNF)-PCC Recommendations
N/A N=26 Mindfulness Based Dementia Care Study
Caregiver Burnout
Primary: Change in Pre-post Scores on the Perceived Stress Scale (PSS) — 4.75 score on a scale
N/A N=93 Development and Implementation of Electronic Decision Aids for Genetic Testing in Inherited Cancer Syndromes
Genetic Testing
Primary: Participant Satisfaction With How Educational Information is Presented in the Decision Aid — 1; 3; 29; 55 Participants
N/A N=193 Cognitive-Behavior Therapy for Posttraumatic Headache
Post-traumatic Headache · PTSD
Primary: Headache-related Disability Scores on the Headache Impact Test 6 (HIT-6) — 66.1; 66.1; 65.2; 61.9 score on a scale — p=<0.001
N/A N=36 Study of HemoCare™ Hemodialysis System for Home Nocturnal Dialysis in Patients With ESRD
End-Stage Renal Disease
Primary: Primary Safety Endpoint — 16.1; 11.6 Adverse Events per 100 Treatments
N/A N=77 Friendship Bench Adaptation to Improve Mental Health & HIV Care Engagement Outcomes Among PLWH and PWID in Vietnam
HIV Infections · Behavioral Symptoms · Depression
Primary: Total Number of Participants Who Were Eligible and Enrolled (Intervention Feasibility) — 75 Participants
Phase 4 N=392 Saxenda in Obesity Services (STRIVE Study)
Obesity · Weight Loss · Diabetes Mellitus
Primary: Weight Loss of ≥15% From Baseline (Complete Cases) — 51; 6 Participants — p=<0.001
Phase 4 N=130 Optimal Protamine Dosing for Heparin Reversal Following Cardiopulmonary Bypass
Coagulation; Intravascular
Primary: Activated Clotting Time — 116; 113 seconds
N/A N=33 Exercise and the Receptor for Advanced Glycation End Products (RAGE)
Diabetes Mellitus, Type 2
Primary: Quantify the Percentage Change in Basal Circulating sRAGE After 12-weeks of Supervised Aerobic Exercise Training. — 24.5; 0.5 Percent Change in sRAGE
Phase 1 N=28 Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and Tablet
Healthy
Primary: Cmax — 4.880; 4.680; 3.860 (μg/mL)
Phase 1 N=34 Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Number of Participants With Treatment-emergent Adverse Events (All Causalities) — 5; 7; 6; 0 Participants